Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEland Oil & Gas Regulatory News (ELA)

  • There is currently no data for ELA

Operations and Financing Update

24 Nov 2014 07:00

RNS Number : 7700X
Eland Oil & Gas PLC
24 November 2014
 



 

24 November 2014

 

Eland Oil & Gas PLC

("Eland" or the "Company")

 

 

Operations and Financing Update

 

Eland Oil & Gas plc (AIM: ELA), an oil & gas production, development and exploration company operating in West Africa with a principal focus on Nigeria, is pleased to announce the following operations and financing update.

 

Highlights

 

·

Opuama Field current average gross production over 3,500 bopd (1,575 bopd net to Elcrest Exploration and Production Nigeria Ltd ("Elcrest"), Eland's joint venture company) based on production days.

 

·

Average uptime on Opuama Field has increased month on month since August. Current average uptime in November 2014 of circa 90%. Current average uptime for Q4 2014 of over 74%.

 

·

Current OML 40 fourth quarter gross production in excess of 140,000 barrels of oil (63,000 barrels net to Elcrest).

 

·

First Oil condition precedent for drawdown of $22 million loan facility with Standard Chartered Bank complete. Availability of debt to be announced in the near term. The Company remains in advanced discussions to target a $75 million reserve based lending facility.

 

·

Current cash balance of $14.7 million as at 21 November 2014.

 

·

Elcrest's next oil lifting is expected to take place in December and is due to be a cargo of circa. 30,000 bbls of crude.

 

·

Dredging operations, which commenced in Q3 2014, continue at the Opuama Field and are nearing completion. Drilling operations planning ongoing for an extended OML 40 development programme in 2015.

 

 

George Maxwell, CEO of Eland Oil & Gas commented:

 

"Achieving a consistent level of production at Opuama has been the main objective of the management so we are very pleased with the positive developments the Company is making.

 

This consistency of production is now delivering the value from OML 40 while also allowing access to debt funding. This is hugely beneficial to our shareholders as it allows the Company to fully develop our assets without requiring any further equity funding.

 

Furthermore, the combination of a lower cost environment and our 5 year petroleum profits tax holiday on OML 40 means our netback per barrel remains significant even in the current economic environment of falling oil prices."

 

 

For further information:

Eland Oil & Gas PLC

+44 (0) 207 016 3180

George Maxwell, CEO

Louis Castro, CFO

Edward Cozens, IR

Canaccord Genuity Limited

+44 (0) 207 523 8000

Henry Fitzgerald-O'Connor

Peter Stewart

FirstEnergy Capital LLP

+44 (0) 207 448 0200

Majid Shafiq

Khalid Ahmed

Citigate Dewe Rogerson

+44 (0) 207 638 9571

Martin Jackson

Shabnam Bashir

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBJBMTMBATTBI
Date   Source Headline
17th Jul 20095:57 pmBUSStudies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease
16th Jul 20092:18 pmRNSResults of Annual General Meeting
13th Jul 200911:30 amBUSElan and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid
10th Jul 20094:59 pmRNSCancellation of UK Listing
8th Jul 20097:00 amBUSElan Announces Webcast of Second Quarter 2009 Financial Results
3rd Jul 200910:57 amRNSBlock Listing Six Monthly Return
2nd Jul 200912:57 pmRNSHolding in Company
2nd Jul 200912:41 pmPRNJohnson & Johnson, Elan Announce Definitive Agreement
1st Jun 20097:00 amBUSSubset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNF? Therapy
29th May 20094:36 pmRNSPrice Monitoring Extension
29th May 20092:00 pmBUSRenee P. Tannenbaum, Pharm.D. Joins Elan as Executive Vice President and Chief Commercial Officer
29th May 200911:54 amBUSTotal Voting Rights
30th Apr 200912:16 pmBUSTotal Voting Rights
27th Apr 20093:35 pmRNSAnnual Report
14th Apr 20095:09 pmRNSHolding(s) in Company
27th Feb 20092:44 pmBUSTotal Voting Rights
25th Feb 200912:23 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
9th Feb 20097:00 amBUSMS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
4th Feb 20092:32 pmRNSHolding(s) in Company
3rd Feb 20093:57 pmRNSHolding(s) in Company
30th Jan 20094:33 pmRNSHolding(s) in Company
28th Jan 20094:24 pmRNSHolding(s) in Company
13th Jan 20097:00 amBUSElan Clarifies Duration of Bapineuzumab Phase 3 Trials
12th Jan 20095:21 pmRNSHolding(s) in Company
12th Jan 20097:00 amBUSTysabri Update
2nd Jan 200912:21 pmRNSTotal Voting Rights
18th Dec 20084:24 pmRNSBlock Listing Six Monthly Return
16th Dec 200811:00 amBUSDirector Declaration
16th Dec 20087:00 amBUSElan to Present at the 27th Annual JP Morgan Healthcare Conference
15th Dec 20083:02 pmBUSTysabri Update
12th Dec 20087:00 amBUSElan Announces Resource Realignment
28th Nov 200810:47 amBUSTotal Voting Rights
25th Nov 20087:00 amBUSMary Stutts to Join Elan as Senior Vice President and Head of Corporate Relations
20th Nov 20087:00 amBUSCarlos V. Paya, MD, PhD, to Join Elan as Company President
3rd Nov 20085:12 pmRNSDirector/PDMR Shareholding
31st Oct 20084:11 pmRNSHolding in Company
31st Oct 200812:01 pmRNSTotal Voting Rights
30th Oct 20084:13 pmRNSTysabri Update
3rd Oct 20085:56 pmRNSHolding in Company
30th Sep 20084:11 pmRNSTotal Voting Rights
22nd Sep 200811:26 amRNSHolding In Company
22nd Sep 20087:00 amRNSTysabri Demonstrates Sustained Improvement
11th Sep 20087:39 amRNSDirector /PDMR Shareholding
1st Sep 20085:02 pmRNSHolding(s) in Company
29th Aug 200810:54 amRNSTotal Voting Rights
28th Aug 20087:00 amRNSInterim Results
14th Aug 20084:12 pmRNSHolding in Company
13th Aug 20085:22 pmRNSHolding in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.